Omnicell's stock surged 10.95% during pre-market trading on Tuesday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.
The healthcare technology provider reported quarterly adjusted earnings of $0.55 per share, beating the consensus estimate of $0.32 by a substantial margin. Revenue for the quarter reached $310 million, representing a 15% year-over-year increase and surpassing analyst forecasts. The company also reported a turnaround to GAAP net income of $11 million, compared to a net loss in the same period last year.
Driving the positive sentiment, Omnicell raised its full-year 2026 guidance, now expecting adjusted EPS in the range of $1.80 to $2.00, compared to previous FactSet estimates of $1.78. The company attributed its strong performance to robust demand for connected devices, disciplined cost management, and growing customer engagement with its Titan XT and OmniSphere platforms.